Publications

All      Ay      Benedict       Cheroutre       Croft       Crotty      Einav       Grifoni       Hogan       Kronenberg      Lisdestam Arlehamn      Myers      Peters      Rao      Reina      Saphire      Schmiedel      Schoenberger      Sette      Sharma      Shresta      Vijayanand      Weiskopf
Altman             Eschweiler      Hedrick       Kawakami      Ley      Pandurangan      Seumois      Von Herrath      
Nov 1, 2003
  • Virology

Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.

Stanfield RL, Ghiara JB, Ollmann Saphire E, Profy AT, Wilson IA.
Dec 13, 2002
  • J Virol

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR.
Jun 20, 2002
  • J Virol

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–>2 mannose residues on the outer face of gp120.

Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR.
Jun 8, 2002
  • J Mol Biol

Contrasting IgG structures reveal extreme asymmetry and flexibility.

Saphire EO, Stanfield RL, Crispin MD, Parren PW, Rudd PM, Dwek RA, Burton DR, Wilson IA.
Mar 28, 2025
  • EBioMedicine

Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.

Cooper CL, Morrow G, Yuan M, Postler TS, Neal ML, Cross RW, Woolsey C, Agans KN, Borisevich V, McNamara RP, Atyeo C, Roy V, Germosen D, Hou F, Li SL, Reiserova L, Choi Y, Wilson A, Wagner D, Wallace-Selman O, Carpov A, Geng F, Frederick DJ, DeStefano J, Ercolini AM, Enriquez AS, Hastie KM, Ramos da Silva S, Sayeed E, Coleman JW, Kilianski A, Alter G, Saphire EO, Aitchison JD, Geisbert TW, Gupta SB, Feinberg MB, Parks CL.
Mar 31, 2025
  • EBioMedicine

Mapping the antibody response to Lassa virus vaccination of non-human primates

Enriquez AS, Avalos RD, Parekh D, Cooper CL, Morrow G, Geisbert TW, Parks CL, Hastie KM, Saphire EO.
Feb 3, 2025
  • Nature Communications

Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane.

Hastie KM, Salie ZL, Ke Z, Halfmann PJ, DeWald LE, McArdle S, Grinyó A, Davidson E, Schendel SL, Hariharan C, Norris MJ, Yu X, Chennareddy C, Xiong X, Heinrich M, Holbrook MR, Doranz B, Crozier I, Kawaoka Y, Branco LM, Kuhn JH, Briggs JAG, Worwa G, Davis CW, Ahmed R, Saphire EO.
Jul 15, 2025
  • Nat Commun

Structural stabilization of the intrinsically disordered SARS-CoV-2 N by binding to RNA sequences engineered from the viral genome fragment

Landeras-Bueno S, Hariharan C, Avalos RD, Norris AS, Snyder DT, Hastie KM, Harkins S, Zandonatti M, Rajamanickam RR, Olmedillas E, Miller R, Shresta S, Wysocki VH, Saphire EO
Jun 24, 2025
  • Trends in Immunology

Infusion of neutralization into Lassa vaccine design.

Li H, Hastie KM, Saphire EO.
Jul 1, 2025
  • Nature Communications

Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses

Meyer M, Gunn BM, Pietzsch C, Subramani C, Kedarinath K, Villarreal PP, Hyde MA, Saphire EO, Crowe JE Jr, Alter G, Himansu S, Carfi A, Bukreyev A.
Jul 1, 2025
  • Nat Microbiol

The GATE glycoprotein complex enhances human cytomegalovirus entry in endothelial cells

Norris MJ, Henderson LA, Siddiquey MNA, Yin J, Yoo K, Brunel S, Mor M, Saphire EO, Benedict CA, Kamil JP
Apr 2, 2025
  • Cell Reports

A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein

Schendel SL, Yu X, Halfmann PJ, Mahita J, Ha B, Hastie KM, Li H, Bedinger D, Troup C, Li K, Kuzmina N, Torrelles JB, Munt JE, Maddocks M, Osei-Twum M, Callaway HM; CoVIC-DB Team; Reece S, Palser A, Kellam P, Dennison SM, Huntwork RHC, Horn GQ, Abraha M, Feeney E, Martinez-Sobrido L, Pino PA, Hicks A, Ye C, Park JG, Maingot B, Periasamy S, Mallory M, Scobey T, Lepage MN, St-Amant N, Khan S, Gambiez A; Coronavirus Immunotherapeutic Consortium; Baric RS, Bukreyev A, Gagnon L, Germann T, Kawaoka Y, Tomaras GD, Peters B, Saphire EO.